Dozee vs Tempus

Tempus has a disclosed valuation of $8.1B, while Dozee's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.1B, compared to Dozee's $20M — a gap of $1B. Combined, the two companies have completed 8 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while Dozee sits at 60/100. That 24-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Dozee was founded by Mudit Dandwate in 2015. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Dozee: Dozee builds a contactless remote patient monitoring system that uses a ballistocardiography sensor placed under a mattress to continuously track heart rate, respiratory rate, blood pressure trends, and sleep quality, transmitting data to an AI analysis platform that generates clinical-grade early warning scores for hospital staff. The system requires no wearables or patient cooperation, enabling continuous monitoring for elderly patients, post-surgical recovery, and ICU step-down units.\n\nThe company raised approximately $20M in Series B funding and has deployed its monitoring systems across hospitals in India and internationally, with evidence of measurable reductions in deterioration events and ICU transfers through early warning. Dozee's central monitoring dashboard allows nursing staff to oversee multiple patients simultaneously with automated deterioration alerts.\n\nContinuous patient monitoring outside of ICU settings is an underserved clinical problem globally, and particularly acute in India where nurse-to-patient ratios in general wards are often insufficient for manual vital sign monitoring. Dozee's contactless approach and AI early warning capability address both the clinical quality and resource efficiency dimensions of this challenge. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Both Dozee and Tempus launched in 2015. Same year, but even a few months' head start matters in AI — early movers lock in data, talent, and customer relationships fast.

Dozee has about 50-200 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Dozee and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.